Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination

Postgrad Med J. 2023 May 22;99(1170):363-364. doi: 10.1136/postgradmedj-2022-141510.

Authors

Adrian Y S Lee^{1

2

3}, Caroline Lee¹, David A Brown^{1

2

3}, Dan Suan^{1

3}

Affiliations

¹ Westmead Hospital, Westmead, New South Wales, Australia.
² Department of Immunopathology, Institute for Clinical Pathology and Medical Research & NSW Health Pathology, Westmead, NSW, Australia.
³ Westmead Clinical School, The University of Sydney, Westmead, NSW, Australia.

PMID: 37227977
DOI: 10.1136/postgradmedj-2022-141510

No abstract available

Keywords: adult dermatology; immunology; neurology; rheumatology.

Publication types

Case Reports

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Dermatomyositis*
Humans
Vaccination

Substances

BNT162 Vaccine
COVID-19 Vaccines
MORC3 protein, human